{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:57:31Z","timestamp":1792619851010,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1124\/dmd.121.000418","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T09:25:13Z","timestamp":1645953913000},"page":"879-887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["Adverse Drug Reactions and Toxicity of the Food and Drug Administration\u2013Approved Antisense Oligonucleotide Drugs"],"prefix":"10.1016","volume":"50","author":[{"given":"Feryal","family":"Alhamadani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Bahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-bo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Manautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000418_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/13543784.2011.547471","article-title":"Mipomersen, an antisense apolipoprotein B synthesis inhibitor","volume":"20","author":"Bell","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/dmd.121.000418_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.121.000418_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ene.13850","article-title":"Insights into the genetic epidemiology of spinal and bulbar muscular atrophy: prevalence estimation and multiple founder haplotypes in the Veneto Italian region","volume":"26","author":"Bertolin","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1124\/dmd.121.000418_bib4","first-page":"4","article-title":"Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives","volume":"31","author":"Beyt\u00eda","year":"2012","journal-title":"Acta Myol"},{"key":"10.1124\/dmd.121.000418_bib72097766","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/dmd.121.000418_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1124\/dmd.121.000418_bib6","first-page":"416","article-title":"Pharmaceutical approval update","volume":"41","author":"Choy","year":"2016","journal-title":"P&T"},{"key":"10.1124\/dmd.121.000418_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1060028018789956","article-title":"Nusinersen: a treatment for spinal muscular atrophy","volume":"53","author":"Claborn","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.121.000418_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne Muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1124\/dmd.121.000418_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000418_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/dmd.121.000418_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.121.000418_bib12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1124\/dmd.121.000418_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"de Smet","year":"1999","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1124\/dmd.121.000418_bib14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib15","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"key":"10.1124\/dmd.121.000418_bib16","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1097\/JCN.0000000000000104","article-title":"Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia","volume":"29","author":"Dixon","year":"2014","journal-title":"J Cardiovasc Nurs"},{"key":"10.1124\/dmd.121.000418_bib17","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1124\/dmd.121.000418_bib18","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1124\/dmd.121.000418_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"10.1124\/dmd.121.000418_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/dmd.121.000418_bib21","first-page":"1508","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","author":"Chakravarthy","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1124\/dmd.121.000418_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ihj.2015.05.020","article-title":"LDL cholesterol, statins and PCSK 9 inhibitors","volume":"67","author":"Gupta","year":"2015","journal-title":"Indian Heart J"},{"key":"10.1124\/dmd.121.000418_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jacl.2014.08.002","article-title":"Liver histology during Mipomersen therapy for severe hypercholesterolemia","volume":"8","author":"Hashemi","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1124\/dmd.121.000418_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.braindev.2021.08.002","article-title":"Epidemiological investigation of spinal muscular atrophy in Japan","volume":"44","author":"Ito","year":"2022","journal-title":"Brain Dev"},{"key":"10.1124\/dmd.121.000418_bib28","first-page":"493","article-title":"Updates on the epidemiology of age-related macular degeneration","volume":"6","author":"Jonas","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1124\/dmd.121.000418_bib1706949","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.omtn.2017.07.003","article-title":"Strategies for in vivo screening and mitigation of hepatotoxicity associated with antisense drugs","volume":"8","author":"Kamola","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.121.000418_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.iio.0000212130.91136.31","article-title":"Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF)","volume":"46","author":"Katz","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"10.1124\/dmd.121.000418_bib30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/0022-2828(88)90583-4","article-title":"Ventricular myosin of the shrew Crocidura russula, correlation with contractile properties","volume":"20","author":"Kessler-Icekson","year":"1988","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/dmd.121.000418_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/oli.2006.16.105","article-title":"Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action","volume":"16","author":"Kornblum","year":"2006","journal-title":"Oligonucleotides"},{"key":"10.1124\/dmd.121.000418_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/dmd.121.000418_bib34","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa122","article-title":"Management of Familial Hypercholesterolemia: Current Status and Future Perspectives","volume":"5","author":"Lui","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1124\/dmd.121.000418_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/dmd.121.000418_bib36","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.280.10.871-JMN0909-6-1","article-title":"First \u201cantisense\u201d drug will treat CMV retinitis","volume":"280","author":"Marwick","year":"1998","journal-title":"JAMA"},{"key":"10.1124\/dmd.121.000418_bib37","first-page":"232","article-title":"Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from duchenne muscular dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"Japan Med Assoc J"},{"key":"10.1124\/dmd.121.000418_bib38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1124\/dmd.121.000418_bib85080595","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience","volume":"8","author":"Mendon\u00e7a","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1124\/dmd.121.000418_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.121.000418_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/nat.2019.0829","article-title":"Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia","volume":"30","author":"Narayanan","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.121.000418_bib41","first-page":"167","article-title":"Pathogenesis and prevention of hepatic steatosis","volume":"11","author":"Nassir","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1124\/dmd.121.000418_bib42","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol Rep"},{"key":"10.1124\/dmd.121.000418_bib43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/jop.2013.0206","article-title":"Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data","volume":"30","author":"Penedones","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/dmd.121.000418_bib44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","article-title":"Fomivirsen","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/jop.2016.0140","article-title":"Cytomegalovirus Retinitis: A Review","volume":"33","author":"Port","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/dmd.121.000418_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2018.11.017","article-title":"Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia","volume":"280","author":"Reeskamp","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1124\/dmd.121.000418_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/ijh-2017-0015","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome with multiorgan failure","volume":"6","author":"Richardson","year":"2017","journal-title":"Int J Hematol Oncol"},{"key":"10.1124\/dmd.121.000418_bib48","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1124\/dmd.121.000418_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1124\/dmd.121.000418_bib50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.121.000418_bib51","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"10.1124\/dmd.121.000418_bib52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/dmd.121.000418_bib53","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1124\/dmd.121.000418_bib54","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-8651-4_3","article-title":"Recent advances and clinical applications of exon inclusion for spinal muscular atrophy","volume":"1828","author":"Son","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.121.000418_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.121.000418_bib57","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000418_bib58","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/dmd.121.000418_bib59","first-page":"11","article-title":"Macugen treatment for wet age-related macular degeneration","volume":"31","author":"Tobin","year":"2006","journal-title":"Insight"},{"key":"10.1124\/dmd.121.000418_bib60","first-page":"484","article-title":"Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/dmd.121.000418_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1124\/dmd.121.000418_bib62","first-page":"119","article-title":"Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong","year":"2014","journal-title":"P&T"},{"key":"10.1124\/dmd.121.000418_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:53:35Z","timestamp":1739937215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624008055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0090955624008055"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000418","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Drug Reactions and Toxicity of the Food and Drug Administration\u2013Approved Antisense Oligonucleotide Drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}